Capital Performance Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Capital Performance Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$260K	Sell	4,515 -18,261	-80%	-$1.05M	0.02%	251
2026 Q1	$1.38M	Buy	22,776 +1,580	+7%	+$92.1K	0.09%	97
2025 Q4	$1.14M	Buy	21,196 +14,965	+240%	+$720K	0.08%	107
2025 Q3	$281K	Buy	6,231 +1,618	+35%	+$75.6K	0.05%	228
2025 Q2	$214K	Sell	4,613 -2,385	-34%	-$117K	0.04%	239
2025 Q1	$427K	Buy	6,998 +812	+13%	+$47.3K	0.09%	121
2024 Q4	$350K	Buy	6,186 +1,225	+25%	+$68.4K	0.11%	81
2024 Q3	$257K	Buy	+4,961	New	+$233K	0.08%	91

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Performance Advisors's BMY Position: Q2 2026 in Review

Capital Performance Advisors reduced its Bristol-Myers Squibb (BMY) stake by 80% in Q2 2026, selling an estimated $1.05M and leaving 4,515 shares worth $260K. The position accounts for 0.02% of the portfolio, ranked #251.

Capital Performance Advisors first reported a position in BMY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.38M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Capital Performance Advisors held 4,515 shares of Bristol-Myers Squibb worth $260K as of Q2 2026.
Capital Performance Advisors sold 18,261 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.05M.
Bristol-Myers Squibb made up 0.02% of Capital Performance Advisors's portfolio in Q2 2026, its #251 holding.
Capital Performance Advisors first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 8 quarters since.
Capital Performance Advisors's Bristol-Myers Squibb position peaked at $1.38M in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.